Send to

Choose Destination
Int J Tuberc Lung Dis. 2014 Nov;18(11):1315-8. doi: 10.5588/ijtld.14.0284.

Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.

Author information

Department of Respiratory Medicine, Medical Research Centre, P D Hinduja National Hospital, Mumbai, India.


Drug-resistant tuberculosis (DR-TB) is a major problem both in India and worldwide. Newer drugs such as TMC-207 (bedaquiline) may have an important role to play in making up an effective drug regimen in such cases. There have been a few reports of bedaquiline use in a non-trial setting from Europe. Our series of five patients is the first series of DR-TB patients from India to receive bedaquiline. All five patients showed striking improvement, with microbiological conversion and an absence of notable adverse effects (e.g., prolonged QTcF), indicating the potential impact of this drug in such a population.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center